Evidence for complement-dependent and -independent inhibition of insulin secretion from clonal β-cells incubated in the presence of sera of newly diagnosed IDDM patients

Journal of Endocrinology

Volumn 164, Issue 2, 2000, Pages 139-147

  Conroy, S J ^a   Abdel Wahab, Y H A ^b   Caraher, E M ^a   Byrne, P M ^a   Murphy, E ^c   Nolan, J ^c   Flatt, P R ^b   Newsholme, P ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY OF ULSTER   (United Kingdom)

^c ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; GLUTAMATE DECARBOXYLASE; INSULIN; PANCREAS ISLET CELL ANTIBODY;

ADULT; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; COMPLEMENT SYSTEM; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; HUMAN CELL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; MALE; PANCREAS FUNCTION; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL; PRIORITY JOURNAL;

EID: 0034006792     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.0.1640139     Document Type: Article

References (30)

1. Boitard, PSC, Debray-Sachs M, Pouplard A, Assan R & Hamburger J 1981 Complement-fixing islet cell antibodies from some diabetic patients alter insulin release in vitro. Diabetes 30 1051-1057.
2. Bottazzo G, Florin-Christensen A & Daniach D 1974 Islet cell antibodies in diabetes mellitus and autoimmune polyendocrine deficiences. Lancet ii 1279-1283.
3. Bottazzo G-F, Dean BM, Gorsuch AN, Cudworth AG & Doniach D 1980 Complement-fixing islet-cell antibodies in type 1 diabetes. Possible monitors of active beta-cell damage. Lancet i 668-672.
4. Bottazzo G-F, Dean BM, McNally JM, MacKay EH, Swift PGF & Gamble DR 1985 In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitus. New England Journal of Mediane 313 353-360.
5. Caraher EM, Conroy SJ & Newsholme P 1999 Evidence for enhanced rates of complement activation in newly diagnosed IDDM patient sera exposed to rat islet cells and complement dependent induction of islet cell apoptosis. Journal of Endocrinology 162 143-153.
6. Cavender DE, Virji MA & Holze-Joost S 1986 Presence of complement-dependent cytotoxic activity against clonally-derived rat islet tumour cells in sera from type-1 (insulin-dependent) diabetic patients and control subjects. Diabetolagia 29 616-622.
7. Comens P, Wolf BA. Unanue ER, Lacy ER & McDaniel ML 1987 Interleukin-1 is a potent modulator of insulin secretion from isolated rat islets of Langerhans. Diabetes 36 963-970.
8. Dobersen MJ, Scharff JE. Ginsberg-Fellner F & Notkins AL 1980 Cytotoxic autoantibodies to beta-cells in the serum of patients with insulin dependent diabetes mellitus. New England Journal of Medicine 303 1493-1498.
9. Dronfield DM, Peakman M & Taylor KW 1995 The effects of islet cell surface antibodies on the metabolic function of mouse islet β-cells in vitro. Acta Diabetologica 32 153-157.
10. Dunger A, Cunningham JM, Delany CA, Lowe JE, Greene MHL, Bone AJ & Green IC 1996 Tumour necrosis factor-α and interferon-γ inhibit insulin secretion and cause DNA damage in unweaned-rat islets. Diabetes 45 183-189.
11. Eisenbarth GS, Morris MA & Scearce RM 1981 Cytotoxic antibodies to cloned rat islet cells in serum of patients with diabetes mellitus. Journal of Clinical Investigation 67 403-408.
12. Heitmeier MR, Scarim AL & Corbett JA 1997 Interferon-γ increases the sensitivity of islets of Langerhans for inducible nitric-oxide synthase expression induced by interleukin-1. Journal of Biological Chemistry 272 13697-13704.
13. Idahl L-A, Sehlin J, Taljedal I-B & Thornell L-A 1980 Cytotoxic activation of complement by mouse pancreatic islet cells. Diabetes 29 636-642.
14. McClenaghan NH, Barnett CR, Ah-Sing E, Abdel-Wahab YHA, O'Harte FPM, Yoon T-W, Swanston-Flatt SK & Flatt PR 1996a Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion. Diabetes 45 1132-1140.
15. McClenaghan NH, Barnett CR, O'Harte FPM & Flatt PR 1996b Mechanisms of ammo acid-induced insulin secretion from the glucose-responsive BRIN-BD11 pancreatic β-cell line. Journal of Endocrinology 151 349-357.
16. McCuish AC, Jordon J, Cambell CJ, Duncan LPJ & Irvine WJ 1974 Antibodies to islet cells in insulin-dependent diabetes mellitus with co-existent autoimmune disease. Lancet ii 1529-1533.
17. Nepom GT 1995 Glutamic acid decarboxylase and other autoantigens in IDDM. Current Opinion in Immunology 7 825-830.
18. 2+ influx in cultured fibroblasts is decreased by the calcium channel antagonist nifedipine or by some bivalent inorganic cations. Biochemical Journal 295 773-779.
19. - channels. Biochemical Pharmacology 57 491-501.
20. O'Brien BA, Harmon BV, Cameron DP & Allan DJ 1997 Apoptosis is the mode of β-cell death responsible for the development of IDDM in the nonobese diabetic (NOD) mouse. Diabetes 46 750-759.
21. Palmer JP, Asplin CM, Clemons P, Lyen K, Tatpoti O, Raghu PK & Paquette TL 1983 Insulin antibodies in insulin dependent diabetics before insulin treatment. Science 222 1337-1339.
22. Radillo O, Nocera A, Leprini A, Barocci S, Mollnes TE, Pocecco M, Pausa M, Valente U, Betterle C & Tedesco F 1996 Complement-fixing islet cell antibodies in Type 1 diabetes can trigger the assembly of the terminal complement complex on human islet cells and are potentially cytotoxic. Clinical Immunology and Immunopathology 79 217-223.
23. Rittenhouse HG, Oxender DL, Pek S & Ar D 1980 Complement-mediated cytotoxicity effects on pancreatic islets with sera from diabetic patients. Diabetes 29 317-322.
24. Sandler S, Andersson A & Hellerstrom C 1987 Inhibitory effects of interleukin-1 on insulin secretion, insulin biosynthesis and oxidative metabolism of isolated rat pancreatic islets. Endocrinology 121 1424-1431.
25. Sensi M, Zuccarini O, Spencer K, Beales P, Pujol-Borrell R & Pozzilli P 1985 In vitro inhibition of insulin release mediated by sera with complement-fixing islet cell antibodies belonging to normal first degree relatives of patients with type-1 diabetes. Diabetes Research 2 1-4.
26. Southern C, Schulster D & Green IC 1990 Inhibition of insulin secretion by interleukin 1 β and tumour necrosis factor-alpha by an L-arginine-dependent nitric oxide generating mechanism. FEBS Letters 276 42-44.
27. Wilkin TJ & Nicholson S 1984 Autoantibodies against human insulin. British Medical Journal 288 349-352.
28. Wilkin TJ, Hammonds P, Mirza I, Bone AJ & Webster K 1988 Graves disease of the β-cell: glucose dysregulation due to islet-cell stimulating antibodies. Lancet ii 1155-1158.
29. Whitaker JF 1969 A general colorimetric procedure for enzymes which are linked to the NADH/NAD system. Clinica Chimica Acta 24 23-37.
30. Zawalich WS & Diaz VA 1986 Interleukin-1 inhibits insulin secretion from isolated perifused rat islets. Diabetes 35 1119-1123.